(HealthDay News) — A child-specific version of the modular model predictive control (MMPC) algorithm is feasible and safe for 5- to 9-year-old children with type 1 diabetes, according to the first outpatient single-hormone artificial pancreas trial in a population of this age, published in Diabetes Care.
Simone Del Favero, PhD, from the University of Padua in Italy, and colleagues conducted an open-label, randomized, crossover trial involving 30 children, aged 5 to 9 years, with type 1 diabetes. The authors compared 4 days with an artificial pancreas with 3 days of parent-managed sensor-augmented pump.
The researchers observed a reduction in overnight time-in-hypoglycemia with the artificial pancreas vs the sensor-augmented pump (median, 0.0% vs 2.2%; P=.002), with no significant change of time-in-target (56.0% and 59.7%, respectively; P=.430); there was an increase in mean glucose (173 mg/dL vs 150 mg/dL; P=.002).
The artificial pancreas was associated with a 3-fold reduction of time-in-hypoglycemia (P<.001) at a cost of reduced time-in-target (P=.022) and increased mean glucose (P<.001).
“This trial, the first outpatient single-hormone artificial pancreas trial in a population of this age, shows feasibility and safety of MMPC in young children,” the researchers wrote. “Algorithm retuning will be performed to improve efficacy.”
Several authors disclosed financial ties to pharmaceutical and medical device companies, several of which provided equipment for the study.